# OnCo record lung-map-s1800a (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/lung-map-s1800a/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "lung-map-s1800a", "NCT03971474" ;
  schema:name "Lung-MAP S1800A: ramucirumab plus pembrolizumab"@en ;
  schema:alternateName "S1800A"@en, "SWOG S1800A"@en ;
  schema:description "In people whose lung cancer had already got past chemotherapy and immunotherapy, the Lung-MAP sub-study S1800A found that a blood-vessel blocker (ramucirumab) plus pembrolizumab helped them live longer than more chemotherapy did. A larger, simpler trial was launched to confirm it."@en ;
  schema:url <https://onco.cc/trials/lung-map-s1800a/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03971474>, <https://doi.org/10.1200/JCO.22.00912> ;
  onco:status "positive" ;
  onco:phase "2" ;
  schema:startDate "2019-05-28" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/pdl1-high-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/pemetrexed/> ;
  onco:companies <https://onco.cc/companies/swog/> ;
  onco:institutions <https://onco.cc/institutions/nci/> ;
  onco:terms <https://onco.cc/terms/master-protocol/>, <https://onco.cc/terms/basket-umbrella-platform/> ;
  onco:trials <https://onco.cc/trials/lung-map/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-reckamp-j-clin-oncol/> .